A multicentre, parallel group, randomised, double blind, placebo-controlled, phase II study evaluating the efficacy and safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) for ischaemic stroke in patients on the non-vitamin K antagonist oral anticoagulant after reversing anticoagulant activity with the specific antidote

Acute ischemic stroke

PRIMARY ENDPOINTS – INTERVENTIONAL PART OF THE STROACT STUDY: 1. Transition from disabling (at admission) to non- disabling deficit (0- yes, 1-no). 2. Change in NIHSS between admission and 7-day follow-up., PRIMARY ENDPOINTS – OBSERVATIONAL PART OF THE STROACT STUDY: 1. Outcome in mRS at 90 days (the proportion of patients with AIS with excellent or good functional outcome assessed with modified Rankin scale (mRS), mRS 0-1 and 0-2 respectively) at 90 days (+/- 3 days) after the admission.

No related papers found yet.

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Poland